Despite rising competition in the market for hepatitis C treatments, Gilead Sciences (GILD) remains the dominant player with its two blockbuster drugs. The Foster City, Calif.-based biotech came under intense scrutiny in late 2013 over the hefty price tags for Sovaldi, which costs $84,000 for 12 weeks of therapy, and Harvoni, which runs $94,500.